BioNTech’s Bold Gamble on mRNA Cancer Therapies Amid Revenue Slump and Restructuring
BioNTech experiences a sharp decline in revenue and profits following the waning demand for COVID-19 vaccines. Despite financial setbacks, BioNTech exceeds market expectations in quarterly earnings. Shifting focus to mRNA-based…